CervoMed Stock Gets Stronger EPS Forecast from HC Wainwright

CervoMed Inc. (NASDAQ:CRVO) – Investment analysts at HC Wainwright increased their FY2026 earnings estimates for shares of CervoMed in a research report issued on Monday, November 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($2.25) per share for the year, up from their prior forecast of ($2.32). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($2.38) per share. HC Wainwright also issued estimates for CervoMed’s Q4 2026 earnings at ($0.50) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.35) EPS, Q3 2027 earnings at ($0.40) EPS, Q4 2027 earnings at ($0.44) EPS and FY2027 earnings at ($1.62) EPS.

Several other research analysts have also recently commented on the company. Roth Capital set a $7.00 price target on CervoMed in a research note on Thursday, August 20th. Weiss Ratings lowered CervoMed from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Wall Street Zen upgraded CervoMed from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Chardan Capital upgraded CervoMed to a “strong-buy” rating in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, CervoMed has a consensus rating of “Moderate Buy” and an average target price of $21.00.

CervoMed Stock Down 4.2%

Shares of NASDAQ CRVO opened at $1.37 on Wednesday. CervoMed has a 1 year low of $1.27 and a 1 year high of $10.00. The stock’s 50-day simple moving average is $2.39 and its 200-day simple moving average is $3.35.

CervoMed (NASDAQ:CRVO) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09.

Institutional Trading of CervoMed

Hedge funds and other institutional investors have recently bought and sold shares of the company. NFSG Corp lifted its holdings in CervoMed by 283.3% during the 3rd quarter. NFSG Corp now owns 11,500 shares of the company’s stock worth $34,000 after buying an additional 8,500 shares during the last quarter. Citizens Financial Group Inc. RI acquired a new position in shares of CervoMed in the 2nd quarter worth approximately $116,000. BlackRock Inc. acquired a new position in shares of CervoMed in the 2nd quarter worth approximately $167,000. Byrne Asset Management LLC increased its holdings in shares of CervoMed by 248.6% in the 2nd quarter. Byrne Asset Management LLC now owns 51,250 shares of the company’s stock valued at $159,000 after acquiring an additional 36,550 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of CervoMed in the 1st quarter valued at approximately $252,000. 25.15% of the stock is owned by institutional investors.

About CervoMed

CervoMed Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company’s lead investigational product is neflamapimod, an orally administered, brain-penetrant small-molecule inhibitor of p38 alpha, an enzyme believed to play a role in neuroinflammation and cognitive decline. CervoMed is primarily evaluating neflamapimod as a potential treatment for dementia with Lewy bodies, a progressive neurological disorder associated with cognitive impairment, fluctuations in attention, visual hallucinations and movement symptoms.